Imexpharm recognised at Top 50 Corporate Sustainability Awards

The awards aim to establish data on sustainable development, assisting the government and relevant social organisations in formulating practical policies to support sustainable growth.

This effort aligns with Vietnam's commitments made at the 26th UN Climate Change Conference to realise its net-zero emission goals by 2050.

Nguyen An Duy (middle), deputy general director and chief financial officer (CFO) of Imexpharm, receives the Top 50 Corporate Sustainability Awards

Additionally, it emphasises the importance of addressing climate change through initiatives in clean energy development, sustainable infrastructure, smart water management, and ecosystem resource management.

With 14 award categories based on the three environmental, social, and governance (ESG) pillars, the awards acknowledge and honour companies across the FDI, listed, and unlisted sectors that contribute to sustainable development, environmental friendliness, and social equity.

As a publicly listed pharmaceutical company with a significant market capitalisation in the industry, Imexpharm has effectively leveraged its sustainable development model within the sector.

From the early days of its establishment, Imexpharm has pursued the goal of sustainable development for the benefit of the community.

With this focus, Imexpharm stands as Vietnam’s largest pharmaceutical company with EU-GMP certification, boasting three EU-GMP facilities and 11 EU-GMP production lines.

Nguyen An Duy receives the award which recognises Imexpharm’s sustainable development strategy for the benefit of the community

Its early investment in high-quality manufacturing technology has facilitated continuous growth and established Imexpharm as the top provider of antibiotics in Vietnam.

Imexpharm currently holds a leading competitive advantage over domestic pharmaceutical companies through its strategy of building EU-GMP certified facilities and making substantial investments in research and development.

The company is leading the trend in EU-GMP factory investments and is well-positioned for a golden period of growth, having already established four manufacturing plants that meet international quality standards.

“We believe that pursuing sustainable development goals will enable our company to continue achieving high growth by providing the market with Vietnamese pharmaceutical products under the Imexpharm brand that meet European quality standards,” said pharmacist Tran Thi Dao, general director of Imexpharm.

The healthcare sector and pharmaceutical companies play a crucial role in achieving the United Nations Sustainable Development Goals to foster community prosperity.

Imexpharm sees green initiatives vital in its sustainable development goal

With a vision of long-term growth and the motto ‘Sharing for Sustainability’, Imexpharm’s sustainable development strategy is built on five core pillars: people, environment, prosperity, collaboration, and building a strong, compassionate organisation.

Imexpharm has achieved significant environmental milestones through its comprehensive sustainability practices, including energy savings, medical waste management, and green initiatives.

All of the company’s facilities are equipped with wastewater treatment systems that meet strict standards.

These systems ensure that all wastewater is treated according to ISO 14001:2015 standards before being released into the environment.

On the social front, the company actively fulfils its responsibilities by providing stable, sustainable employment, contributing to local economic growth, meeting tax obligations, and participating in various social welfare programmes.

As a public company listed since 2006, Imexpharm is committed to becoming a leader in sustainable development across all of its operations.

This dedication is evidenced by the numerous awards the company received in 2023, including Top 10 Mid-cap Companies with the Best Corporate Governance; 50 Best Listed Companies in Vietnam 2023; Top 10 Reputable Pharmaceutical Companies in 2023; Ngoi Sao Thuoc Viet Award, Top 50 Typical Sustainable Development Enterprises; Top 5 Best Workplaces in Healthcare; Board of The Year Award 2023 by the Vietnam Institute of Directors for its sound and diverse governance structures; and Imexpharm stock being ranked for the second consecutive year in the Top 20 Sustainable Development Stocks.

Concurrently, the company has achieved record-breaking business results, with a 17.5 per cent annual compound growth rate in earnings before interest, taxes, depreciation, and amortisation over the past five years, positioning it towards its goal of reaching half a billion US dollars in revenue.

These achievements underscore and validate Imexpharm's corporate governance model, which is becoming increasingly scientific and professional.

As a leading Vietnamese pharmaceutical company, Imexpharm meets international standards of good governance and aligns with its sustainable development strategy based on ESG criteria.

“Investing in ESG is an opportunity to demonstrate our company's vision and mission in addressing community issues. This foundation has enabled us to promote sustainable practices, thereby fostering innovation and operation as well as business efficiency in line with international standards,” said Imexpharm’s leader.

According to Imexpharm’s leadership, the company is making strides towards a more sustainable future by incorporating ESG factors into its development strategy.

This holistic approach involves assessing environmental impacts from the outset of drug development and product formulation.

It encompasses the use of less toxic chemicals, the pursuit of more efficient production methods, and the design of processes to minimise waste.

Additionally, the company is establishing a green manufacturing foundation, aiming to reduce environmental impact during production by utilising renewable energy sources, minimising water usage, and optimising processes.

At the same time, Imexpharm is committed to creating a sustainable supply chain, ensuring that raw materials are sourced responsibly and that transportation minimises emissions, which are crucial aspects of a sustainable supply chain.

Imexpharm's manufacturing experience and EU-GMP certified production lines equip the company with the capability to meet international quality standards, opening opportunities to join the global pharmaceutical supply chain.

With high-quality products that meet European standards, Imexpharm has successfully exported to new markets such as Mongolia and signed export contracts with markets including Singapore, Malaysia, the Philippines, and Hong Kong.

These strategies lay the groundwork for the company’s vision for 2030, with the expectation that revenue will triple, marking a significant step in solidifying the company’s position in the global market.

The achievements of leading pharmaceutical companies like Imexpharm contribute to realising the development strategy of the pharmaceutical industry for the period up to 2030 and the vision for 2045, aiming to position Vietnam as a high-value pharmaceutical production hub in the region.

“Integrating ESG principles requires significant investment and effort. Balancing profitability with environmental sustainability and social responsibility in the pharmaceutical sector can be challenging. Nevertheless, pharmaceutical companies that embrace ESG principles will be well-positioned for long-term success and to contribute to a prosperous and sustainable community,” added Imexpharm's general director.

BCI Asia Awards honour Top 10 architecture firms in Vietnam Vietnam's 10 most-active property developers, architecture firms, and contractors were awarded at the annual BCI Asia Awards ceremony on May 31 at Sheraton Saigon Grand Opera Hotel.

JustMarkets wins double at 2024 UF Awards The 2024 iFX Expo International was held in Limassol, Cyprus between June 18-20, bringing together global brands, C-level professionals, startups, and fintech innovators to exchange experiences.

Imexpharm and Deloitte Vietnam launch flagship project on resource management Imexpharm Pharmaceuticals JSC and Deloitte Vietnam celebrated the launch of a project to upgrade its enterprise resource planning system leveraging flagship SAP S/4HANA solution on July 3 at Imexpharm's headquarters in Dong Thap province.